PathoVax LLC is a Johns Hopkins start-up biotechnology company headquartered in Baltimore, Maryland. Founded in 2014, the company has been focused on different medical applications for its proprietary Papillomavirus Virus-like Particle (VLP) platform.


Management & Operations Team

Joshua Wang Ph.D.
Co-Founder & CEO
John Troyer Ph.D.
Chief Operations
Ken Matsui Ph.D.
Immunology & Biology
Wenbin Lai Ph.D., MBA
Chemistry, Manufacturing & Controls Advisor (Singapore)
Nattha Ingavat Ph.D.
Scientist I (Biochemistry)
Philip Storm Ph.D.
Scientist I

Business Advisory Board

Robert Silverman
Chairman of Business Advisory Board
Eric Richman, MBA
Business Advisor
Roger Pomerantz M.D., FACP
Business Advisor
Solomon Langermann, Ph.D
Business Advisor
Alain Rolland Pharm.D., Ph.D.

Scientific, Clinical Advisory Board, and Collaborators

Richard Roden, Ph.D
Co-director of Viral Oncology, Johns Hopkins School of medicine

Reinhard Kirnbauer, MD
Director of Viral Oncology,
Medical University Vienna
David Masopust, Ph.D
Professor of Microbiology and Immunology, University of Minnesota
Warner Huh, M.D
Professor and Division Director of the Division of Gynecologic Oncology at the University of Alabama at Birmingham.
Iain Tan, MBBS, MCRP (UK), FAMS (Med Onco), Ph.D.
Associate Professor & Senior Consultant, Division of Colorectal Cancer, National Cancer Center Singapore (Collaborator)
John Schiller, Ph.D
NIH Distinguished Investigator (Collaborator)